(PDF) Quantification of Minimal Residual Disease in

Quantification of Minimal Residual Disease in Patients With E1a2 BCR-ABL-positive Acute Lymphoblastic Leukemia Using a Real-Time RT-PCR Assay

Leukemia - United Kingdom

doi 10.1038/sj.leu.2402483

Full Text

Open PDF

Abstract

Available in full text

Date

June 1, 2002

Authors

Publisher

Springer Science and Business Media LLC

Related search

Standardisation and Consensus Guidelines for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph + ALL) by Real-Time Quantitative Reverse Transcriptase PCR of E1a2 BCR-ABL1

English

Detection of BCR-ABL Transcripts in Chronic Myeloid Leukemia (CML) Using a ‘Real Time’ Quantitative RT-PCR Assay

English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica

Hematology

2015

English

Quantitative Analysis of TEL/AML1 Fusion Transcripts by Real-Time RT-PCR Assay in Childhood Acute Lymphoblastic Leukemia

English

Monitoring of Minimal Residual Disease (MRD) by Real-Time Quantitative Reverse Transcription PCR (RQ-RT-PCR) in Childhood Acute Myeloid Leukemia With AML1/ETO Rearrangement

English

Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients With Earlier Quantification of Minimal Residual Disease

PLoS ONE

Multidisciplinary

2013

English

Prospective BCR-ABL Analysis by Polymerase Chain Reaction (RT-PCR) in Adult Acute B-Lineage Lymphoblastic Leukemia: Reliability of RT-nested-PCR and Comparison to Cytogenetic Data

English

Effect of a Selective Abl Tyrosine Kinase Inhibitor, STI571, on in Vitro Growth of BCR-ABL-positive Acute Lymphoblastic Leukemia Cells

English

Comparison of Competitive-Nested PCR and Real-Time PCR in Detecting BCR-ABL Fusion Transcripts in Chronic Myeloid Leukemia Patients

English

Amanote Research

Quantification of Minimal Residual Disease in Patients With E1a2 BCR-ABL-positive Acute Lymphoblastic Leukemia Using a Real-Time RT-PCR Assay

Leukemia - United Kingdom

doi 10.1038/sj.leu.2402483

Full Text

Abstract

Categories

Date

Authors

Publisher

Related search

Standardisation and Consensus Guidelines for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph + ALL) by Real-Time Quantitative Reverse Transcriptase PCR of E1a2 BCR-ABL1

Detection of BCR-ABL Transcripts in Chronic Myeloid Leukemia (CML) Using a ‘Real Time’ Quantitative RT-PCR Assay

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Quantitative Analysis of TEL/AML1 Fusion Transcripts by Real-Time RT-PCR Assay in Childhood Acute Lymphoblastic Leukemia

Monitoring of Minimal Residual Disease (MRD) by Real-Time Quantitative Reverse Transcription PCR (RQ-RT-PCR) in Childhood Acute Myeloid Leukemia With AML1/ETO Rearrangement

Improving the Identification of High Risk Precursor B Acute Lymphoblastic Leukemia Patients With Earlier Quantification of Minimal Residual Disease

Prospective BCR-ABL Analysis by Polymerase Chain Reaction (RT-PCR) in Adult Acute B-Lineage Lymphoblastic Leukemia: Reliability of RT-nested-PCR and Comparison to Cytogenetic Data

Effect of a Selective Abl Tyrosine Kinase Inhibitor, STI571, on in Vitro Growth of BCR-ABL-positive Acute Lymphoblastic Leukemia Cells

Comparison of Competitive-Nested PCR and Real-Time PCR in Detecting BCR-ABL Fusion Transcripts in Chronic Myeloid Leukemia Patients